Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234308 | 1.00 | PARP1 (0.63) | PARP1LMNAHDAC6ENPP1AR | |
| SCHEMBL19748474 | 0.96 | PARP1 (0.64) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL29655259 | 0.96 | PARP1 (0.64) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL19748607 | 0.90 | PARP1 (0.68) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL29655224 | 0.90 | PARP1 (0.68) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL19748359 | 0.88 | PARP1 (0.60) | PARP1LMNAENPP1CYP3A4CYP2C9 | |
| SCHEMBL29655038 | 0.88 | PARP1 (0.60) | PARP1LMNAENPP1CYP3A4CYP2C9 | |
| SCHEMBL29483966 | 0.87 | PARP1 (0.72) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL4572876 | 0.87 | PARP1 (0.72) | PARP1LMNAENPP1ARCYP3A4 | |
| SCHEMBL19747669 | 0.85 | PARP1 (0.63) | PARP1LMNAENPP1ARCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-109843874-B | Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer | 加利福尼亚大学董事会 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | PARP1 3/4885LMNA 1010/4885HDAC6 18/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | PARP1 3/4885LMNA 1010/4885HDAC6 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.